Current Heart Failure Reports

, Volume 2, Issue 2, pp 59–64

The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitors—What has time told us?

  • Mary Rose Fabi
  • John R. Teerlink

Abstract

The neurohormonal hypothesis for the pathogenesis of heart failure found an early champion in the angiotensinconverting enzyme (ACE) inhibitors. More recently, the β-blockers and aldosterone receptor antagonists have provided significant support by demonstrating marked additive clinical benefit. Within this context, angiotensin receptor blockers (ARBs) were specifically designed to antagonize one of the most potent contributors to the development and progression of heart failure, angiotensin. This review discusses the recent evidence for the addition of ARBs to standard therapy with ACE inhibitors and suggests how this evidence may be used to care for patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Siragy HM, Xue C, Abadir P, Carey RM: Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 2005, 45:133–137.PubMedGoogle Scholar
  2. 2.
    Johren O, Dendorfer A, Dominiak P: Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res 2004, 62:460–467.PubMedCrossRefGoogle Scholar
  3. 3.
    Hartman JC: The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 1995, 60:789–792.PubMedCrossRefGoogle Scholar
  4. 4.
    Imig JD: ACE inhibition and bradykinin-mediated renal vascular responses: EDHF involvement. Hypertension 2004, 43:533–535.PubMedCrossRefGoogle Scholar
  5. 5.
    Cruden NL, Witherow FN, Webb DJ, et al.: Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 2004, 24:1043–1048.PubMedCrossRefGoogle Scholar
  6. 6.
    Pouleur HG, Konstam MA, Udelson JE, Rousseau MF: Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. J Am Coll Cardiol 1993, 22:43A-48A.PubMedCrossRefGoogle Scholar
  7. 7.
    Roig E, Perez-Villa F, Morales M, et al.: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21:53–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Urata H, Kinoshita A, Misono KS, et al.: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990, 265:22348–22357.PubMedGoogle Scholar
  9. 9.
    Timmermans PB, Duncia JV, Carini DJ, et al.: Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens 1995, 9(Suppl 5):S3-S18.PubMedGoogle Scholar
  10. 10.
    Kim S, Yoshiyama M, Izumi Y, et al.: Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001, 103:148–154.PubMedGoogle Scholar
  11. 11.
    Yoshida J, Yamamoto K, Mano T, et al.: AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 2004, 43:686–691.PubMedCrossRefGoogle Scholar
  12. 12.
    Shimizu T, Okamoto H, Chiba S, et al.: Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. Jpn Heart J 2002, 43:531–543.PubMedCrossRefGoogle Scholar
  13. 13.
    Kim YK, Mankad S, Kim SJ, et al.: Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction. J Card Fail 2003, 9:238–245.PubMedCrossRefGoogle Scholar
  14. 14.
    Azizi M, Chatellier G, Guyene TT, et al.: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995, 92:825–834.PubMedGoogle Scholar
  15. 15.
    Gremmler B, Kunert M, Schleiting H, Ulbricht LJ: Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. Eur J Heart Fail 2000, 2:183–187.PubMedCrossRefGoogle Scholar
  16. 16.
    Tonkon M, Awan N, Niazi I, et al.: A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract 2000, 54:11–14, 16–18.PubMedGoogle Scholar
  17. 17.
    Struckman DR, Rivey MP: Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure. Ann Pharmacother 2001, 35:242–248.PubMedCrossRefGoogle Scholar
  18. 18.
    Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874–1880.PubMedCrossRefGoogle Scholar
  19. 19.
    Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003, 26:2268–2274.PubMedCrossRefGoogle Scholar
  20. 20.
    Wade VL, Gleason BL: Dual blockade of the renin-angiotensin system in diabetic nephropathy. Ann Pharmacother 2004, 38:1278–1282.PubMedCrossRefGoogle Scholar
  21. 21.
    Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-convertingenzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124. This small, single-center study of 366 patients demonstrated that combination therapy with trandolapril and losartan significantly decreased time to worsening of renal function and improved survival, compared with therapy with either agent alone.PubMedCrossRefGoogle Scholar
  22. 22.
    McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056–1064. This important exploratory pilot study assesses the effect of candesartan, enalapril, and their combination on multiple endpoints, including neurohormonal changes and ventricular remodeling. Combination therapy reduced neurohormones and limited progressive increase in ventricular volumes in patients with heart failure.PubMedGoogle Scholar
  23. 23.
    Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675. The Val-HeFT trial demonstrated that the addition of valsartan to a standard heart failure regimen, including ACE inhibitors, improved morbidity and mortality, primarily through reduced heart failure hospitalizations. Subgroup analysis also demonstrated dramatic benefits of valsartan compared with placebo in ACE inhibitor-intolerant patients.PubMedCrossRefGoogle Scholar
  24. 24.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771. The CHARM-Added trial is part of the CHARM program, and it addressed the question of the utility of adding candesartan to a standard heart failure regimen, including ACE inhibitors and β-blockers. Candesartan significantly reduced the combined endpoint of cardiovascular death and heart failure hospitalizations and decreased cardiovascular death, compared with placebo.PubMedCrossRefGoogle Scholar
  25. 25.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906. The VALIANT trial enrolled patients after MI with evidence of heart failure and randomized them to valsartan, captopril, or the combination. The study demonstrated the noninferiority of valsartan to captopril with respect to mortality, but the combination had no additional benefit.PubMedCrossRefGoogle Scholar
  26. 26.
    Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717. The Randomized Aldactone Evaluation Study enrolled patients with symptomatic heart failure and demonstrated that the addition of spironolactone, an aldosterone antagonist, to a regimen with ACE inhibitors improved survival.PubMedCrossRefGoogle Scholar
  27. 27.
    Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321. The Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study enrolled patients after MI with evidence of heart failure and randomized them to therapy with eplerenone, a selective aldosterone antagonist, or placebo. Patients treated with eplerenone had decreased all-cause mortality and less frequent hospitalizations.PubMedCrossRefGoogle Scholar
  28. 28.
    Bozkurt B, Agoston I, Knowlton AA: Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003, 41:211–214.PubMedCrossRefGoogle Scholar
  29. 29.
    Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543–551.PubMedCrossRefGoogle Scholar
  30. 30.
    Pitt B, Segal R, Martinez FA, et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747–752.PubMedCrossRefGoogle Scholar
  31. 31.
    Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587. ELITE II was the first mortality trial using an ARB in patients with heart failure. The study demonstrated a nonsignificant increase in mortality in the losartan-treated patients, compared with placebo. Although some suggest that the losartan was significantly underdosed, the study clearly refutes any suggestion of a survival benefit for losartan.PubMedCrossRefGoogle Scholar
  32. 32.
    Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772–776.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • Mary Rose Fabi
  • John R. Teerlink
    • 1
  1. 1.San Francisco VA Medical CenterSan FranciscoUSA

Personalised recommendations